Otsuka Pharmaceutical has announced that it will fully acquire clinical-stage biotech company Transcend Therapeutics through its US subsidiary, Otsuka America. The deal, valued at up to $1.225 billion, is expected to close in the second quarter of 2026, pending customary approvals.
Under the agreement, Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones.
Founded in 2021, Transcend is developing rapid-acting neuroplastogens for neuropsychiatric conditions. Its lead candidate, TSND‑201 (methylone), is being advanced as a potential treatment for post-traumatic stress disorder (PTSD) and other psychiatric disorders.
“Although treatment options for PTSD remain limited, TSND‑201 is generating expectations as a potential paradigm‑shifting therapy in the field of psychiatry,” said Makoto Inoue, president and representative director of Otsuka.
“By combining Otsuka's long‑standing expertise in the psychiatric and neurological fields with Transcend's innovative approach, we will advance the development of TSND‑201 in close collaboration with regulatory authorities to bring this new treatment option to patients.”
TSND‑201 works by promoting monoamine release in the brain, enhancing neuroplasticity—the ability of neural circuits to reorganize, which is critical for memory and emotional regulation. Unlike hallucinogenic compounds, it does not act on the serotonin 5-HT2A receptor, making it a non-hallucinogenic option.
Phase 2 results, published in JAMA Psychiatry in February 2026, showed rapid and robust effects in adults with PTSD. The therapy received FDA Breakthrough Therapy designation in July 2025, and Phase 3 patient recruitment is underway in the U.S.
“We founded Transcend to bring a fundamentally new treatment to patients with PTSD—one that is rapid-acting and accessible,” said Blake Mandell, CEO and co-founder of Transcend.
“Otsuka's leadership and longstanding commitment in neuroscience reflect the same dedication to patients that has driven our team from day one, and we are proud to continue advancing TSND-201 together in service of that shared mission.”
The addition of TSND‑201 strengthens Otsuka’s portfolio with a novel mechanism of action and positions the company to accelerate the development of next-generation therapies for PTSD and other psychiatric disorders.
